Drug intelligence / Profile preview

IBIO123

Development stage: Phase 2
Lead developer: Immune Biosolutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Inhalation

Overview

**IBIO123** is an investigational inhaled fixed-dose cocktail of three fully human recombinant neutralizing monoclonal antibodies developed by Immune Biosolutions for treatment and post-exposure prophylaxis of COVID-19. The antibodies bind distinct regions of the SARS-CoV-2 spike glycoprotein, aiming to neutralize viral entry directly in the respiratory tract following nebulized inhalation. Phase 1/2 studies evaluated IBIO123 in mild-to-moderate and severe COVID-19, and a Phase 2 study evaluated post-exposure prophylaxis in household contacts. ([europepmc.org](https://europepmc.org/article/MED/37619584))

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on IBIO123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBIO123.

Explore the full profile